Subtype
Non-Invasive Bladder Urothelial Neoplasm
CI-CAN-00006139Explore in graph →
Non-malignant3 active trials
- NCIt
- C158374
Loading cancer entity…
Subtype
CI-CAN-00006139Explore in graph →
Clinical trials
10 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05375903 | A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | completed | Phase 1 | 51 | UroGen Pharma Ltd.INDUSTRY | 3 | Jan 14, 2026 | clinicaltrials |
| NCT04496219 | Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer | completed | Phase 2 | 45 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT04647981 | Diagnostic Performance Evaluation Study of the Xpert® Bladder Cancer Monitor Test.(Xpert Bladder) | completed | — | 320 | Clinique Beau SoleilOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT01304173 |
Data updated 22 days agoSource updated Jan 14, 2026source: clinicaltrials
| Retrospective Chart Review of Valstar |
| completed |
| — |
| 113 |
| Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY |
| 1 |
| Feb 19, 2014 |
| clinicaltrials |